ECSP045243A - Péptidos macrocíclicos activos contra el virus de la hepatitis C - Google Patents

Péptidos macrocíclicos activos contra el virus de la hepatitis C

Info

Publication number
ECSP045243A
ECSP045243A EC2004005243A ECSP045243A ECSP045243A EC SP045243 A ECSP045243 A EC SP045243A EC 2004005243 A EC2004005243 A EC 2004005243A EC SP045243 A ECSP045243 A EC SP045243A EC SP045243 A ECSP045243 A EC SP045243A
Authority
EC
Ecuador
Prior art keywords
alkyl
virus
active against
against hepatitis
macrocyclic peptides
Prior art date
Application number
EC2004005243A
Other languages
English (en)
Inventor
Montse Llinas-Brunet
Vida J Gorys
Original Assignee
Boehringer Ingelheim Ca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Ca Ltd filed Critical Boehringer Ingelheim Ca Ltd
Publication of ECSP045243A publication Critical patent/ECSP045243A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Compuestos de fórmula I, en la que R1 es hidroxi o NHSO2R1A en el que R1A es alquilo (C1-8), cicloalquilo(C3-7) o {alquilo(C1-6)-cicloalquilo(C3-7)}, que están todos ellos sustituidos opcionalmente desde 1 a 3 veces con halo, ciano, nitro, O-alquilo(C1-6), amido, amino o fenilo, o R1A es arilo C6 o C10 que está sustituido opcionalmente desde 1 a 3 veces con halo, ciano, nitro, alquilo(C1-6), O-alquilo(C1-6), amido, amino o fenilo; R2 es cicloalquilo(C5-6) y R3 es ciclopentilo; o una sal farmacéuticamente aceptable de los mismos, útiles como inhibidores de la proteasa N3 del VHC.
EC2004005243A 2002-01-30 2004-08-20 Péptidos macrocíclicos activos contra el virus de la hepatitis C ECSP045243A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002369711A CA2369711A1 (en) 2002-01-30 2002-01-30 Macrocyclic peptides active against the hepatitis c virus

Publications (1)

Publication Number Publication Date
ECSP045243A true ECSP045243A (es) 2004-09-28

Family

ID=27626541

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005243A ECSP045243A (es) 2002-01-30 2004-08-20 Péptidos macrocíclicos activos contra el virus de la hepatitis C

Country Status (26)

Country Link
US (1) US20030181363A1 (es)
EP (1) EP1472278B1 (es)
JP (1) JP4040578B2 (es)
KR (1) KR20040077899A (es)
CN (1) CN1639187A (es)
AR (1) AR038330A1 (es)
AT (1) ATE414098T1 (es)
BR (1) BR0307297A (es)
CA (1) CA2369711A1 (es)
DE (1) DE60324660D1 (es)
EA (1) EA007738B1 (es)
EC (1) ECSP045243A (es)
ES (1) ES2316718T3 (es)
HR (1) HRP20040689A2 (es)
MX (1) MXPA04007462A (es)
NO (1) NO20043591L (es)
NZ (1) NZ534929A (es)
PE (1) PE20030818A1 (es)
PL (1) PL371007A1 (es)
RS (1) RS67004A (es)
SA (1) SA03230569B1 (es)
TW (1) TW200307692A (es)
UA (1) UA78014C2 (es)
UY (1) UY27630A1 (es)
WO (1) WO2003064455A2 (es)
ZA (1) ZA200405639B (es)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4080541B2 (ja) 1996-10-18 2008-04-23 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ、特にｃ型肝炎ウイルスｎｓ３プロテアーゼの阻害因子
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
AU2002248147B2 (en) 2000-11-20 2006-04-06 Bristol-Myers Squibb Company Hepatitis C tripeptide inhibitors
US6867185B2 (en) * 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
AU2003248535A1 (en) 2002-05-20 2003-12-12 Bristol-Myers Squibb Company Heterocyclicsulfonamide hepatitis c virus inhibitors
EP1505945B1 (en) 2002-05-20 2008-11-05 Bristol-Myers Squibb Company Substituted cycloalkyl p1' hepatitis c virus inhibitors
JP4312718B2 (ja) 2002-05-20 2009-08-12 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルス阻害剤
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US20050075279A1 (en) * 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US20050159345A1 (en) * 2002-10-29 2005-07-21 Boehringer Ingelheim International Gmbh Composition for the treatment of infection by Flaviviridae viruses
US7176208B2 (en) * 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
UY28323A1 (es) 2003-05-21 2004-12-31 Boehringer Ingelheim Int Compuestos inhibidores de la hepatitis c
JP4928261B2 (ja) 2003-06-18 2012-05-09 トランザイム・ファーマ・インコーポレイテッド モチリン受容体の大環状拮抗薬
TW201127828A (en) 2003-09-05 2011-08-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
JP4704342B2 (ja) * 2003-09-22 2011-06-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎ウイルスに対し活性な大環状ペプチド
WO2005037214A2 (en) * 2003-10-14 2005-04-28 Intermune, Inc. Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
EP1687021B1 (en) 2003-11-20 2013-11-06 Boehringer Ingelheim International GmbH Method of removing transition metals, especially from metathesis reaction products
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP1699558B1 (en) * 2003-12-08 2009-03-11 Boehringer Ingelheim International GmbH Removal of ruthenium by-product by supercritical fluid processing
JP4682155B2 (ja) * 2004-01-21 2011-05-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎ウイルスに対して活性な大環状ペプチド
AR047793A1 (es) 2004-01-30 2006-02-22 Medivir Ab Inhibidores de la serina proteasa ns-3 del vhc
ES2431314T3 (es) 2004-02-20 2013-11-26 Boehringer Ingelheim International Gmbh Inhibidores de polimerasa vírica
WO2005095403A2 (en) * 2004-03-30 2005-10-13 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
US7202332B2 (en) 2004-05-27 2007-04-10 New York University Methods for preparing internally constrained peptides and peptidomimetics
PL382845A1 (pl) * 2004-07-16 2008-01-21 Gilead Sciences, Inc. Związki przeciwwirusowe
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
CA2573346C (en) 2004-07-20 2011-09-20 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
EP1794179A1 (en) * 2004-09-17 2007-06-13 Boehringer Ingelheim International Gmbh Ring-closing metathesis process in supercritical fluid
CA2577831A1 (en) * 2004-09-17 2006-03-30 Boehringer Ingelheim International Gmbh Process for preparing macrocyclic hcv protease inhibitors
CA2583472A1 (en) * 2004-10-01 2006-04-13 Chao Lin Hcv ns3-ns4a protease inhibition
US20070249637A1 (en) * 2004-10-21 2007-10-25 Collins Michael R Inhibitors Of Hepatitis C Virus Protease, And Compositions And Treatments Using The Same
MY141025A (en) 2004-10-29 2010-02-25 Vertex Pharma Dose forms
DE102005002336A1 (de) * 2005-01-17 2006-07-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Durchführung von kontinuierlichen Olefin-Ringschluss-Metathesen in komprimiertem Kohlendioxid
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2006242475B2 (en) 2005-05-02 2011-07-07 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US7592336B2 (en) 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7470664B2 (en) * 2005-07-20 2008-12-30 Merck & Co., Inc. HCV NS3 protease inhibitors
MX2008001166A (es) 2005-07-25 2008-03-18 Intermune Inc Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c.
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
JP4705984B2 (ja) * 2005-08-01 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｈｃｖｎｓ３プロテアーゼ阻害剤としての大環状ペプチド
US8076365B2 (en) 2005-08-12 2011-12-13 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US8119592B2 (en) 2005-10-11 2012-02-21 Intermune, Inc. Compounds and methods for inhibiting hepatitis C viral replication
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US8039475B2 (en) 2006-02-27 2011-10-18 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
CA2646229A1 (en) 2006-03-16 2007-09-27 Vertex Pharmaceuticals Incorporated Deuterated hepatitis c protease inhibitors
GB0609492D0 (en) * 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
RU2008152171A (ru) * 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
EP2049474B1 (en) 2006-07-11 2015-11-04 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US7718612B2 (en) * 2007-08-02 2010-05-18 Enanta Pharmaceuticals, Inc. Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
EP2054388A4 (en) 2006-08-17 2009-10-28 Boehringer Ingelheim Int VIRAL POLYMERASE INHIBITORS
AU2007309546A1 (en) 2006-10-24 2008-05-02 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. HCV NS3 protease inhibitors
US8138164B2 (en) 2006-10-24 2012-03-20 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
CN101583372A (zh) * 2006-10-24 2009-11-18 默克公司 Hcv ns3蛋白酶抑制剂
EP2086982B1 (en) 2006-10-27 2018-08-29 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
CA2667032A1 (en) 2006-10-27 2008-05-15 Merck & Co., Inc. Hcv ns3 protease inhibitors
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
GB0625345D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2008075103A1 (en) 2006-12-20 2008-06-26 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Antiviral indoles
GB0625349D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
DK2111396T3 (da) * 2007-02-08 2013-11-04 Janssen R & D Ireland HCV-Inhiberende makrocykliske phenylcarbamater
HRP20120330T1 (hr) 2007-02-27 2012-05-31 Vertex Pharmaceuticals Incorporated Sukristali i farmaceutski pripravci koji ih sadrže
WO2008106058A2 (en) 2007-02-27 2008-09-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
MX2009012093A (es) * 2007-05-10 2010-01-25 Intermune Inc Nuevos peptidos inhibidores de la replicacion del virus de la hepatitis c.
AP2009005073A0 (en) 2007-06-29 2009-12-31 Gilead Sciences Inc Antiviral compounds
TW200918524A (en) * 2007-06-29 2009-05-01 Gilead Sciences Inc Antiviral compounds
AU2008271116B2 (en) 2007-06-29 2012-09-20 Gilead Sciences, Inc. Antiviral compounds
WO2009010785A1 (en) 2007-07-17 2009-01-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Macrocyclic indole derivatives for the treatment of hepatitis c infections
US8927569B2 (en) 2007-07-19 2015-01-06 Merck Sharp & Dohme Corp. Macrocyclic compounds as antiviral agents
US8242140B2 (en) 2007-08-03 2012-08-14 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US8492546B2 (en) 2007-08-30 2013-07-23 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
US8419332B2 (en) * 2007-10-19 2013-04-16 Atlas Bolt & Screw Company Llc Non-dimpling fastener
MX2010006210A (es) 2007-12-05 2010-08-10 Enanta Pharm Inc Inhibidores de serina proteasa de hcv de tripeptido fluorado.
EA201000948A1 (ru) 2007-12-19 2011-02-28 Бёрингер Ингельхайм Интернациональ Гмбх Ингибиторы вирусной полимеразы
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
ES2437147T3 (es) 2008-02-04 2014-01-09 Idenix Pharmaceuticals, Inc. Inhibidores de serina proteasa macrocíclicos
BRPI0911260A2 (pt) 2008-04-15 2015-09-29 Intermune Inc composto, composição farmacêutica, método de inibição de atividade da protease de ns3/ns4 in, vitro e usos de compostos
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102014911A (zh) 2008-04-28 2011-04-13 默沙东公司 Hcv ns3蛋白酶抑制剂
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5529120B2 (ja) 2008-05-29 2014-06-25 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルス阻害剤
EP2310095B1 (en) 2008-07-22 2012-08-29 Merck Sharp & Dohme Corp. Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2009316472B2 (en) 2008-11-20 2015-07-09 Achillion Pharmaceuticals, Inc. Cyclic carboxamide compounds and analogues thereof as of Hepatitis C virus
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2012512878A (ja) * 2008-12-19 2012-06-07 ギリアード サイエンシーズ， インコーポレイテッド Ｈｃｖｎｓ３プロテアーゼインヒビター
MX2011007195A (es) 2009-01-07 2013-07-12 Scynexis Inc Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).
EP2396028A2 (en) 2009-02-12 2011-12-21 Vertex Pharmceuticals Incorporated Hcv combination therapies comprising pegylated interferon, ribavirin and telaprevir
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
CA2758072A1 (en) 2009-04-08 2010-10-14 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
MX2011012155A (es) 2009-05-13 2012-02-28 Enanta Pharm Inc Compuestos macrociclicos como inhibidores del virus de hepatitis c.
US8232246B2 (en) * 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
US8828930B2 (en) 2009-07-30 2014-09-09 Merck Sharp & Dohme Corp. Hepatitis C virus NS3 protease inhibitors
AR077712A1 (es) 2009-08-05 2011-09-14 Idenix Pharmaceuticals Inc Inhibidores de serina proteasa macrociclica
BR112012014899A2 (pt) 2009-12-18 2017-03-14 Idenix Pharmaceuticals Inc composto, composição farmacêutica, método para tratar ou prevenir uma infecção por vírus de hepatite c em um sujeito, método para tratar , prevenir ou melhorar um ou mais sintomas de uma doença hepática ou distúrbio associado a uma infecção por vírus de hepatite c em um sujeito, método para inibir a replicação de um vírus em um hospedeiro, método para inibir a replicação de um vírus
WO2011094489A1 (en) 2010-01-29 2011-08-04 Vertex Pharmaceuticals Incorporated Therapies for treating hepatitis c virus infection
WO2011156545A1 (en) 2010-06-09 2011-12-15 Vertex Pharmaceuticals Incorporated Viral dynamic model for hcv combination therapy
US20120014912A1 (en) 2010-07-14 2012-01-19 Vertex Pharmaceuticals Incorporated Palatable pharmaceutical composition
SG188618A1 (en) 2010-09-21 2013-04-30 Enanta Pharm Inc Macrocyclic proline derived hcv serine protease inhibitors
US8951964B2 (en) 2010-12-30 2015-02-10 Abbvie Inc. Phenanthridine macrocyclic hepatitis C serine protease inhibitors
JP2014502620A (ja) 2010-12-30 2014-02-03 エナンタ ファーマシューティカルズ インコーポレイテッド 大環状ｃ型肝炎セリンプロテアーゼ阻害剤
WO2012109398A1 (en) 2011-02-10 2012-08-16 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
WO2012109646A1 (en) 2011-02-11 2012-08-16 Vertex Pharmaceuticals Incorporated Treatment of hcv in hiv infection patients
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20130195797A1 (en) 2012-01-31 2013-08-01 Vertex Pharmaceuticals Incorporated High potency formulations of vx-950
CN102617705B (zh) * 2012-02-16 2014-12-31 上海纬诺医药科技有限公司 抑制丙肝病毒复制的大环类化合物
BR112015007887A2 (pt) 2012-10-08 2017-07-04 Abbvie Inc compostos úteis para produzir inibidores hcv protease
JP6154474B2 (ja) 2012-10-19 2017-06-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014070974A1 (en) 2012-11-05 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
JP6342922B2 (ja) 2013-03-07 2018-06-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
US20160229866A1 (en) 2013-09-20 2016-08-11 Idenix Pharmaceuticals Inc. Hepatitis c virus inhibitors
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
WO2015134560A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Solid forms of a flaviviridae virus inhibitor compound and salts thereof
US20170135990A1 (en) 2014-03-05 2017-05-18 Idenix Pharmaceuticals Llc Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
CN110256536B (zh) * 2019-05-13 2022-09-13 中国人民解放军第二军医大学 一种抗丙型肝炎病毒感染合成肽及其应用
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors
CN117105928B (zh) * 2023-08-22 2024-03-26 上海蓝木化工有限公司 一种蛋白酶抑制剂及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6867185B2 (en) * 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus

Also Published As

Publication number Publication date
US20030181363A1 (en) 2003-09-25
ATE414098T1 (de) 2008-11-15
NZ534929A (en) 2006-08-31
PL371007A1 (en) 2005-06-13
KR20040077899A (ko) 2004-09-07
CA2369711A1 (en) 2003-07-30
PE20030818A1 (es) 2003-10-30
JP4040578B2 (ja) 2008-01-30
HRP20040689A2 (en) 2005-06-30
UA78014C2 (en) 2007-02-15
MXPA04007462A (es) 2005-07-13
RS67004A (sr) 2006-10-27
DE60324660D1 (de) 2008-12-24
ES2316718T3 (es) 2009-04-16
EA007738B1 (ru) 2006-12-29
TW200307692A (en) 2003-12-16
AR038330A1 (es) 2005-01-12
JP2005524632A (ja) 2005-08-18
BR0307297A (pt) 2004-12-21
ZA200405639B (en) 2005-07-01
EA200400886A1 (ru) 2005-02-24
EP1472278B1 (en) 2008-11-12
SA03230569B1 (ar) 2007-03-05
CN1639187A (zh) 2005-07-13
EP1472278A2 (en) 2004-11-03
NO20043591L (no) 2004-08-27
UY27630A1 (es) 2003-08-29
WO2003064455A3 (en) 2004-02-05
WO2003064455A2 (en) 2003-08-07

Similar Documents

Publication Publication Date Title
ECSP045243A (es) Péptidos macrocíclicos activos contra el virus de la hepatitis C
ECSP045226A (es) Tripéptidos inhibidores de la hepatitis c
AR038382A1 (es) Compuesto inhibidor de la hepatitis c
ATE443713T1 (de) Makrozyklische peptide mit wirkung gegen das hepatitis-c-virus
UY28722A1 (es) Peptidos macrociclicos activos contra el virus del a hepatitis c
BRPI0414571A (pt) peptìdeos macrocìclicos ativos contra o vìrus da hepatite c
EP1771454A4 (en) PEPTIDE ANALOGUE AS HEPATITIS C HEMMER
CO5261542A1 (es) Nuevos derivados tripeptidos como inhibidores de la hepatitis c, comprendiendo sus racematos, diasteroisomeros y procedimiento de preparacion
DK1615613T3 (da) Quinoxalinyl-makrocykliske hepatitis C serin protease-inhibitorer
PE20040589A1 (es) Tiazolidinonas y su preparacion como medicamentos
CL2004001161A1 (es) Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
DE602004029866D1 (de) Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
UY28423A1 (es) Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc.-
UY30527A1 (es) Tetrazolilos macrociclicos como inhibidores de serina proteasa de hepatitis c
UY30437A1 (es) Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c
AR039226A2 (es) Compuestos utiles como intermediarios de preparacion y procedimientos
Zhou et al. Discovery and SAR studies of methionine–proline anilides as dengue virus NS2B-NS3 protease inhibitors
UY30391A1 (es) Compuesto de oximilo aciclico inhibidores de proteasa de hepatitis c
PE20080355A1 (es) Compuestos peptidicos como inhibidores de proteasa de serina del virus de hepatitis c
EA200300523A1 (ru) Ингибиторы трипептидил пептидазы
TH62682A (es)